A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer.
The purpose of this study is to evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma.
Participants will not be paid for their participation.
- IRB Number: 1807487019 (EA2165)
- Research Study Identifier: TX9335
- Principal Investigator: Patrick Loehrer, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required